Sofia Hakansson Buch

Vice President for Cell Therapy CMC • Novo Nordisk

Sofia leads the Cell Therapy CMC unit, in Måløv, Denmark, being responsible for analytical, formulation and process development. She has been driving the establishment of a cell therapy in-house manufacturing site in California and is also the link between Novo Nordisk R&D and Product Supply for the cell therapy portfolio. Sofia is a member of the Novo Nordisk cell therapy governance board and of several joint steering committees with external partners. In total, Sofia has worked 16 years at Novo Nordisk in various positions such as research scientist in the Protein Chemistry unit, Diabetes Research Unit, as line manager within recombinant technologies (heading up the mammalian and yeast platforms in Global Research) and as project leader for different projects (both therapeutic and technology projects). Sofia´s basic education is a MSc in Chemistry and a PhD in Molecular Biotechnology. 

Also speaking

Troels Jordansen

CEO • GlycoStem

Stuart Curbishley

Head of Business and Project Development – Advanced Therapies • University of Birmingham

Arthur Stril

Chief Business Officer • Cellectis

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.